308 related articles for article (PubMed ID: 15204232)
1. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
Lilleberg J; Ylönen V; Lehtonen L; Toivonen L
Scand Cardiovasc J; 2004 May; 38(2):80-4. PubMed ID: 15204232
[TBL] [Abstract][Full Text] [Related]
2. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
[TBL] [Abstract][Full Text] [Related]
5. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
Mebazaa A; Erhardt L
Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
[TBL] [Abstract][Full Text] [Related]
6. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
[TBL] [Abstract][Full Text] [Related]
7. The effect of levosimendan during long-term amiodarone treatment in dogs.
Papp JG; Pollesello P; Varró A; Végh A; Udvary E
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):27-32. PubMed ID: 16867167
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
9. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
Nieminen MS; Sandell EP
Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
[TBL] [Abstract][Full Text] [Related]
11. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.
Tasouli A; Papadopoulos K; Antoniou T; Kriaras I; Stavridis G; Degiannis D; Geroulanos S
Eur J Cardiothorac Surg; 2007 Oct; 32(4):629-33. PubMed ID: 17702589
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
[TBL] [Abstract][Full Text] [Related]
15. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
Husebye T; Eritsland J; Müller C; Sandvik L; Arnesen H; Seljeflot I; Mangschau A; Bjørnerheim R; Andersen GØ
Eur J Heart Fail; 2013 May; 15(5):565-72. PubMed ID: 23288914
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties.
Kowalczyk M; Banach M; Lip GY; Kozłowski D; Mikhailidis DP; Rysz J
Int J Clin Pract; 2010 Jul; 64(8):1148-54. PubMed ID: 20642713
[TBL] [Abstract][Full Text] [Related]
17. Safety of levosimendan and other calcium sensitizers.
Lehtonen L; Mills-Owens P; Akkila J
J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S70-6. PubMed ID: 8907134
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
Kota B; Prasad AS; Economides C; Singh BN
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
[TBL] [Abstract][Full Text] [Related]
20. Peripartum cardiomyopathy: a new successful setting for levosimendan.
Benezet-Mazuecos J; de la Hera J
Int J Cardiol; 2008 Jan; 123(3):346-7. PubMed ID: 17324479
[No Abstract] [Full Text] [Related]
[Next] [New Search]